Get PACE removed from clinical guidelines – sign the petition!
Sasha invites you to sign a new petition to the HHS to protect patients against the PACE trial, CBT and GET ...
Discuss the article on the Forums.

Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected

Discussion in 'Antivirals, Antibiotics and Immune Modulators' started by Ema, Apr 3, 2014.

  1. Ema

    Ema Senior Member

    Messages:
    4,276
    Likes:
    5,901
    Midwest USA
    I have the whole paper if anyone is interested...



    J Clin Virol. 2006 Dec;37 Suppl 1:S69-75.
    Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts.
    Naesens L1, Bonnafous P, Agut H, De Clercq E.
    Author information

    Abstract
    BACKGROUND:
    HHV-6 replication requires complex and poorly understood interactions between viral and cellular factors.

    OBJECTIVES:
    Several natural compounds or broad-acting pharmacological agents were studied in an attempt to discover new targets for anti-HHV-6 therapy.

    STUDY DESIGN:
    The antiviral activity was determined in human T-lymphoblasts, using HHV-6A (GS)-infected HSB-2 cells, HHV-6B (Z29)-infected MOLT-3 cells and HHV- 6B (HST)-infected MT4 cells. Virus replication was measured by CPE and qPCR assay. Foscarnet was included as the reference compound.

    RESULTS:
    Among the 15 natural compounds tested, only 'red marine algae' (an extract rich in sulfated polysaccharides) exhibited strong activity when added during virus adsorption. Among the broad-acting pharmacological agents, chloroquine, artemisinin, hypericin, ribavirin, resveratrol and glycyrrhizic acid were all inactive. Amantadine produced a reproducible inhibition of HHV-6 replication, albeit at relatively high concentrations. Except for lamotrigine, which was moderately active against HHV-6B, several antiepileptic drugs were shown to have no activity. We included several compounds which we previously described as potent HHV-6 inhibitors, i.e., the non-nucleoside inhibitor CMV423 and the acyclic nucleoside phosphonate analogues cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-3-deazaadenine. The latter compound exhibited remarkable anti-HHV-6 activity.

    CONCLUSION:
    Further optimization of compounds belonging to diverse classes of antiherpetic agents, for their specific action against HHV-6, is warranted.
     
    Iquitos, heapsreal and SOC like this.

See more popular forum discussions.

Share This Page